The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.
about
Mu-opioid antagonists for opioid-induced bowel dysfunctionEmerging therapies for patients with symptoms of opioid-induced bowel dysfunctionAlvimopanTreatment of opioid-induced gut dysfunction[Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review].Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytesManaging opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.Policy alternatives for treatments for rare diseases.Recent advances in the use of opioids for cancer painManagement of opioid-induced gastrointestinal effects in patients receiving palliative care.Methylnaltrexone in the treatment of opioid-induced constipationAnticipating and treating opioid-associated adverse effects.Methods for the assessment of small-bowel and colonic transit.Assessing and managing opiate-induced constipation in adults with cancer.Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects.The Impact of Opioid Treatment on Regional Gastrointestinal Transit.Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.Measurement of Gastrointestinal and Colonic Motor Functions in Humans and AnimalsMethylnaltrexone use in a seventeen-month-old female with progressive cancer and rectal prolapse.Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Emerging drugs for chronic constipation.Effectiveness of two opioid antagonists in treating opioid-induced constipation.Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness.Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration.Opioid-induced constipation: challenges and therapeutic opportunities.Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.Methylnaltrexone for the treatment of opioid-induced constipation.The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilitiesTreatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility.Established and emerging methods for assessment of small and large intestinal motility.Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation.Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.Methylnaltrexone and alvimopan: economic management of opioid-induced bowel dysfunction.Pharmacologic treatment of opioid-induced constipation.Meta-analysis of oro-cecal transit time in fasting subjects.
P2860
Q24243268-B360C028-A176-493E-BF80-32B38740CC44Q27010907-C6AA3BD6-DC3F-42F1-B99C-09CE8F91C582Q28249359-B5995E74-2FCF-4DCA-AA33-72A59CBDFF15Q28284578-6E34B709-984E-4C67-BC25-A97A1ACD1E9FQ31104772-3C924B85-20D7-4865-A633-0BE5C6E7001CQ33296232-7AEC16B0-8409-4FDE-8622-A7446CC9F6D9Q33593875-3AFA1210-5527-4FBC-815D-4D6EEFEEB743Q33715430-4C495568-62FB-4182-9959-1E86C35BC311Q33973870-EA1CB14F-9960-4113-8484-6DCAE0A9BDFCQ34334611-4DF2F87A-76F0-4312-A5AA-AF5BB1DB4AF4Q34418203-81A9D253-BB87-4C5A-AF02-A691D6F208CAQ34523889-0E796AB2-4AA9-4251-9ABA-8BAA73370756Q35026245-32A06D27-AE07-4CD5-AD7E-EB99818D08A0Q35194392-3D4C7DFA-7A99-4F8C-9A20-3084F3F6BB16Q35724278-1E57931A-5BB4-44B5-8794-FABF83CE9494Q35778556-D1857D41-7642-40A4-9E6D-E50D60724CC0Q36458384-9EB32AC8-F8BF-4AA7-96DA-B1E2F10607FDQ36762661-7ADD0E46-BA85-4CA9-A53B-1FAD686BC2A6Q36936210-FDC89C3F-829D-4D94-9C99-439ACDA51C61Q37261844-BB4BC352-EFF7-448A-8D38-CE71D968F6ADQ37293417-1A945ED3-9437-4351-A257-715850728039Q37491434-B29A6CF9-4DEE-42F8-90F6-D31F7915F835Q37570550-DA746689-068A-44B2-A62A-411E22F28BC0Q37601903-4C32260C-0100-4925-82DA-6C5F0456D852Q37611847-5FB70BB0-FC52-48D6-A3C4-6C37A2D05B63Q37827493-46C14574-DA47-4F2F-B8D1-E7BCC6FF9761Q37846099-484E85DA-49E2-4E4A-97B7-150D54E57693Q37916266-350FB5C0-2C65-4740-8DC1-28152F990307Q37954521-BC7AC8A9-0EEB-4231-8C9C-4913E55DC6E1Q37960501-1F579095-7F94-4A99-8523-0545B187C11FQ37993108-916F7660-7EE8-4D5E-BEA9-894EF2CCFDB0Q38069607-1AC85A3C-A992-4E12-A47B-8A757C5218DFQ38116004-2E1F68F8-603F-48DF-B506-B0C6F1B0E7A4Q38202638-70C1737F-0DA5-440C-9DC9-B5AB1C4107FBQ39021750-55B14B44-469C-4AA3-8ADC-1CDB0866264AQ39234260-51FF3693-669E-4D22-A65A-C44090239ECCQ43075560-DD3D3482-5EE9-49B0-B9AE-737E4F23C081Q43266400-8CD33AD8-01C0-4935-B460-689C1CDCB50FQ43442255-F1A7F02E-283A-42D8-81A6-3704EAC040B3Q43474298-69066F28-821E-4E81-B881-BCF803BBDFE3
P2860
The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
The safety and efficacy of ora ...... ay in oral-cecal transit time.
@en
The safety and efficacy of ora ...... ay in oral-cecal transit time.
@nl
type
label
The safety and efficacy of ora ...... ay in oral-cecal transit time.
@en
The safety and efficacy of ora ...... ay in oral-cecal transit time.
@nl
prefLabel
The safety and efficacy of ora ...... ay in oral-cecal transit time.
@en
The safety and efficacy of ora ...... ay in oral-cecal transit time.
@nl
P2093
P1476
The safety and efficacy of ora ...... ay in oral-cecal transit time.
@en
P2093
P304
P356
10.1016/S0009-9236(97)90197-1
P407
P577
1997-04-01T00:00:00Z